{"doc_id": "32768938", "type of study": "Therapy", "title": "", "abstract": "Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a.\nThe present study investigates the differences in inflammatory agents alterations, immune function, and leukocyte differential count evaluation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome after the recommended Chinese medicine prescription of Yidu-toxicity blocking lung decoction.\nA total of 40 patients with yidu-toxicity blocking lung syndrome, diagnosed as severe pneumonia of SARS-COV-2 following the latest Chinese national recommendations for the diagnosis and treatment of pneumonia caused by SARS-COV-2 (the 5th edition), were recruited.\nThey were randomly divided into the pure western medicine therapy group (PWM) and integrated into Chinese and Western medicine therapy group (ICW).\nThe general strategies were given to both groups according to the national recommendations, and the ICW group was given Yidu-toxicity blocking lung decoction extraorally.\nA radioimmunoassay method was adopted to detect the content of IL-6, IL-8,IL-2R,TNF-\u03b1, procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) in sera.\nFlow cytometry was used to determine the peripheral blood lymphocyte subsets (the levels of CD3+, CD4+, CD8+, and the ratios of CD4+/CD8+).\nThe white blood cell counts (WBC#), neutrophils count(N#), and lymphocyte counts (L#) were measured using a fully automatic blood rheological instrument.\nThe t-test or Rank Sum Test and Spearman analysis were conducted to evaluate the differences.\nThe results showed that IL-6 (P = 0.013) and TNF-\u03b1 (P = 0.035) levels in the PWM group were significantly higher than those in the ICW group after treatment.\nInfection related indicators such as WBC#, N#, L#, hs-CRP showed no differences.\nThe analysis showed that there was no statistical difference in the values of CD4 and CD8 between the two groups.\nBy the end of Day 29, all patients were discharged and the final cure rate for both group were 100 %.\nTaken together, we conclude that Yidu-toxicity blocking lung decoction could relieve inflammation of SARS-COV-2 patients with yidu-toxicity blocking lung syndrome by eliminating inflammatory agents.\nCM can serve as a complementary medication to western medicine, which should be highlighted in clinical settings.\nCopyright \u00a9 2020 The Authors.\nPublished by Elsevier Masson SAS.. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "severe pneumonia", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 82}, {"term": "SARS-COV-2", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 96}, {"term": "severe pneumonia", "negation": "affirmed", "UMLS": {}, "start": 149, "end": 165}, {"term": "SARS-COV-2", "negation": "affirmed", "UMLS": {}, "start": 169, "end": 179}, {"term": "Yidu-toxicity blocking lung syndrome", "negation": "affirmed", "UMLS": {}, "start": 194, "end": 230}, {"term": "yidu-toxicity blocking lung syndrome", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 64}, {"term": "severe pneumonia of SARS-COV-2", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 110}, {"term": "SARS-COV-2", "negation": "affirmed", "UMLS": {}, "start": 102, "end": 112}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a .", "Evidence Elements": {"Participant": [{"term": "severe pneumonia", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 82}, {"term": "SARS-COV-2", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 96}], "Intervention": [{"term": "Yidu-toxicity blocking lung decoction", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 37, "has_relation": "N/A"}, {"term": "Yidu-toxicity blocking lung syndrome", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 147, "has_relation": "N/A"}], "Outcome": [{"term": "inflammation", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 62}, {"term": "IL-6", "negation": "affirmed", "UMLS": {}, "start": 163, "end": 167}, {"term": "TNF-a", "negation": "affirmed", "UMLS": {}, "start": 172, "end": 177}], "Observation": [{"term": "ameliorates", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 49}, {"term": "eliminating", "negation": "affirmed", "UMLS": {}, "start": 151, "end": 162}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The present study investigates the differences in inflammatory agents alterations , immune function , and leukocyte differential count evaluation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome after the recommended Chinese medicine prescription of Yidu-toxicity blocking lung decoction .", "Evidence Elements": {"Participant": [{"term": "severe pneumonia", "negation": "affirmed", "UMLS": {}, "start": 149, "end": 165}, {"term": "SARS-COV-2", "negation": "affirmed", "UMLS": {}, "start": 169, "end": 179}, {"term": "Yidu-toxicity blocking lung syndrome", "negation": "affirmed", "UMLS": {}, "start": 194, "end": 230}], "Intervention": [{"term": "Yidu-toxicity blocking", "negation": "affirmed", "UMLS": {}, "start": 194, "end": 216, "has_relation": "N/A"}], "Outcome": [{"term": "inflammatory agents alterations", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 81}, {"term": "immune function", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 99}, {"term": "leukocyte differential count evaluation", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 145}], "Observation": [{"term": "differences", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 46}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "Yidu-toxicity blocking", "has_relation": "N/A"}], "Observation": "differences", "Outcome": "inflammatory agents alterations", "Count": ""}, {"Intervention": [{"term": "Yidu-toxicity blocking", "has_relation": "N/A"}], "Observation": "differences", "Outcome": "immune function", "Count": ""}, {"Intervention": [{"term": "Yidu-toxicity blocking", "has_relation": "N/A"}], "Observation": "differences", "Outcome": "leukocyte differential count evaluation", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "A total of 40 patients with yidu-toxicity blocking lung syndrome , diagnosed as severe pneumonia of SARS-COV-2 following the latest Chinese national recommendations for the diagnosis and treatment of pneumonia caused by SARS-COV-2 ( the 5th edition ) , were recruited .", "Evidence Elements": {"Participant": [{"term": "yidu-toxicity blocking lung syndrome", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 64}, {"term": "severe pneumonia of SARS-COV-2", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 110}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "They were randomly divided into the pure western medicine therapy group ( PWM ) and integrated into Chinese and Western medicine therapy group ( ICW ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "pure western medicine therapy", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 65, "has_procedure": [{"text": "pure western medicine therapy", "maps_to": "C0087111:therapy", "start": 0, "end": 29}], "has_relation": "N/A"}, {"term": "Chinese and Western medicine therapy", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 136, "has_procedure": [{"text": "western medicine therapy", "maps_to": "C0087111:therapy", "start": 12, "end": 36}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The general strategies were given to both groups according to the national recommendations , and the ICW group was given Yidu-toxicity blocking lung decoction extraorally .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Yidu-toxicity blocking lung decoction", "negation": "affirmed", "UMLS": {}, "start": 121, "end": 158, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "A radioimmunoassay method was adopted to detect the content of IL-6 , IL-8 , IL-2R , TNF-\u03b1 , procalcitonin ( PCT ) and high-sensitivity C-reactive protein ( hs-CRP ) in sera .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "content of IL-6 , IL-8 , IL-2R , TNF-\u03b1 , procalcitonin ( PCT", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 112}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Flow cytometry was used to determine the peripheral blood lymphocyte subsets ( the levels of CD3+ , CD4+ , CD8+ , and the ratios of CD4+/CD8+ ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "peripheral blood lymphocyte subsets", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 76}, {"term": "levels of CD3+ , CD4+ , CD8+", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 111}, {"term": "ratios", "negation": "affirmed", "UMLS": {}, "start": 122, "end": 128}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The white blood cell counts ( WBC # ) , neutrophils count ( N# ) , and lymphocyte counts ( L # ) were measured using a fully automatic blood rheological instrument .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "white blood cell counts ( WBC # )", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 37}, {"term": "neutrophils count ( N# )", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 64}, {"term": "lymphocyte counts ( L", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 92}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The t-test or Rank Sum Test and Spearman analysis were conducted to evaluate the differences .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The results showed that IL-6 ( P = 0.013 ) and TNF-\u03b1 ( P = 0.035 ) levels in the PWM group were significantly higher than those in the ICW group after treatment .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "PWM", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 84, "has_procedure": [{"text": "pure western medicine therapy", "maps_to": "C0087111:therapy", "start": 0, "end": 29}], "has_relation": "N/A"}], "Outcome": [{"term": "IL-6", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 28}, {"term": "TNF-\u03b1", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 52}, {"term": "levels", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 73}], "Observation": [{"term": "significantly higher", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 116}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "PWM", "has_procedure": [{"text": "pure western medicine therapy", "maps_to": "C0087111:therapy", "start": 0, "end": 29}], "has_relation": "N/A"}], "Observation": "significantly higher", "Outcome": "IL-6", "Count": ""}, {"Intervention": [{"term": "PWM", "has_procedure": [{"text": "pure western medicine therapy", "maps_to": "C0087111:therapy", "start": 0, "end": 29}], "has_relation": "N/A"}], "Observation": "significantly higher", "Outcome": "TNF-\u03b1", "Count": ""}, {"Intervention": [{"term": "PWM", "has_procedure": [{"text": "pure western medicine therapy", "maps_to": "C0087111:therapy", "start": 0, "end": 29}], "has_relation": "N/A"}], "Observation": "significantly higher", "Outcome": "levels", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Infection related indicators such as WBC # , N # , L # , hs-CRP showed no differences .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Infection related indicators", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 28}, {"term": "WBC #", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 42}, {"term": "N #", "negation": "affirmed", "UMLS": {}, "start": 45, "end": 48}, {"term": "L", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 52}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The analysis showed that there was no statistical difference in the values of CD4 and CD8 between the two groups .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "between the two groups", "negation": "negated", "UMLS": {}, "start": 90, "end": 112, "has_relation": "N/A"}], "Outcome": [{"term": "values of CD4 and CD8", "negation": "negated", "UMLS": {}, "start": 68, "end": 89}], "Observation": [{"term": "statistical difference", "negation": "negated", "UMLS": {}, "start": 38, "end": 60}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "By the end of Day 29 , all patients were discharged and the final cure rate for both group were 100 % .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "both group", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 90, "has_relation": "N/A"}], "Outcome": [{"term": "discharged", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 51}, {"term": "final cure rate", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 75}], "Observation": [{"term": "100", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 99}], "Count": [{"term": "all patients", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 35}]}, "Evidence Propositions": [{"Intervention": {"term": "both group", "has_relation": "N/A"}, "Observation": "100", "Outcome": "final cure rate", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Taken together , we conclude that Yidu-toxicity blocking lung decoction could relieve inflammation of SARS-COV-2 patients with yidu-toxicity blocking lung syndrome by eliminating inflammatory agents .", "Evidence Elements": {"Participant": [{"term": "SARS-COV-2", "negation": "affirmed", "UMLS": {}, "start": 102, "end": 112}], "Intervention": [{"term": "Yidu-toxicity blocking lung decoction", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 71, "has_relation": "N/A"}, {"term": "yidu-toxicity blocking lung syndrome", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 163, "has_relation": "N/A"}], "Outcome": [{"term": "inflammation", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 98}, {"term": "inflammatory", "negation": "affirmed", "UMLS": {}, "start": 179, "end": 191}], "Observation": [{"term": "relieve", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 85}, {"term": "eliminating", "negation": "affirmed", "UMLS": {}, "start": 167, "end": 178}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "CM can serve as a complementary medication to western medicine , which should be highlighted in clinical settings .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 The Authors .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier Masson SAS . . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}